Best for
Mobile

Posted
Teva Pharmaceutical Industries Limited is a drug manufacturers-specialty & generic business based in the US. Teva Pharmaceutical Industries shares (TEVA.US) are listed on the NYSE and all prices are listed in US Dollars. Teva Pharmaceutical Industries employs 40,039 staff and has a trailing 12-month revenue of around $16.7 billion.
Best for
Mobile
Best for
Low-cost
Best for
All rounder
Best for
Beginners
Latest market close | $N/A |
---|---|
52-week range | $6.25 - $13.56 |
50-day moving average | $10.7079 |
200-day moving average | $10.1964 |
Wall St. target price | $11.82 |
PE ratio | 872 |
Dividend yield | N/A (0%) |
Earnings per share (TTM) | $0.004 |
Other fees may apply. Your capital is at risk.
All investing should be regarded as longer term. The value of your investments can go up and down, and you may get back less than you invest. Past performance is no guarantee of future results. If you’re not sure which investments are right for you, please seek out a financial adviser. Capital at risk.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Valuing Teva Pharmaceutical Industries stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Teva Pharmaceutical Industries's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Teva Pharmaceutical Industries's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 872x. In other words, Teva Pharmaceutical Industries shares trade at around 872x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
Teva Pharmaceutical Industries's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.9526. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Teva Pharmaceutical Industries's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Teva Pharmaceutical Industries's EBITDA (earnings before interest, taxes, depreciation and amortisation) is a whopping $4.6 billion.
The EBITDA is a measure of a Teva Pharmaceutical Industries's overall financial performance and is widely used to measure a its profitability.
Revenue TTM | $16.7 billion |
---|---|
Operating margin TTM | 18.19% |
Gross profit TTM | $7.5 billion |
Return on assets TTM | 3.54% |
Return on equity TTM | -32.82% |
Profit margin | -24.18% |
Book value | $8.753 |
Market capitalisation | $13.1 billion |
TTM: trailing 12 months
There are currently 33.9 million Teva Pharmaceutical Industries shares held short by investors – that's known as Teva Pharmaceutical Industries's "short interest". This figure is 3.1% up from 32.9 million last month.
There are a few different ways that this level of interest in shorting Teva Pharmaceutical Industries shares can be evaluated.
Teva Pharmaceutical Industries's "short interest ratio" (SIR) is the quantity of Teva Pharmaceutical Industries shares currently shorted divided by the average quantity of Teva Pharmaceutical Industries shares traded daily (recently around 7.6 million). Teva Pharmaceutical Industries's SIR currently stands at 4.45. In other words for every 100,000 Teva Pharmaceutical Industries shares traded daily on the market, roughly 4450 shares are currently held short.
However Teva Pharmaceutical Industries's short interest can also be evaluated against the total number of Teva Pharmaceutical Industries shares. In this case Teva Pharmaceutical Industries's short interest could be expressed as 0.03% of the outstanding shares (for every 100,000 Teva Pharmaceutical Industries shares in existence, roughly 30 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Teva Pharmaceutical Industries.
Find out more about how you can short Teva Pharmaceutical Industries stock.
Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like Teva Pharmaceutical Industries.
When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.
Total ESG risk: 58.8
Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and Teva Pharmaceutical Industries's overall score of 58.8 (as at 01/01/2019) is pretty weak – landing it in it in the 76th percentile of companies rated in the same sector.
ESG scores are increasingly used to estimate the level of risk a company like Teva Pharmaceutical Industries is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).
Environmental score: 77.02/100
Teva Pharmaceutical Industries's environmental score of 77.02 puts it squarely in the 87th percentile of companies rated in the same sector. This could suggest that Teva Pharmaceutical Industries is a laggard in its sector in terms of its environmental impact, and exposed to a greater level of risk.
Social score: 47.2/100
Teva Pharmaceutical Industries's social score of 47.2 puts it squarely in the 58th percentile of companies rated in the same sector. This could suggest that Teva Pharmaceutical Industries is pretty average in terms of looking after its workforce and social impact.
Governance score: 65.26/100
Teva Pharmaceutical Industries's governance score puts it squarely in the 81st percentile of companies rated in the same sector. That could suggest that Teva Pharmaceutical Industries is a laggard in its sector in terms of responsible leadership, and exposed to a greater level of risk.
Controversy score: 3/5
ESG scores also evaluate any incidences of controversy that a company has been involved in. A high-profile company, Teva Pharmaceutical Industries scored a 3 out of 5 for controversy – a middle-of-the-table result reflecting that Teva Pharmaceutical Industries hasn't always managed to keep its nose clean.
Teva Pharmaceutical Industries Limited was last rated for ESG on: 2019-01-01.
Total ESG score | 58.8 |
---|---|
Total ESG percentile | 76.26 |
Environmental score | 77.02 |
Environmental score percentile | 87.16 |
Social score | 47.2 |
Social score percentile | 58.24 |
Governance score | 65.26 |
Governance score percentile | 80.64 |
Level of controversy | 3 |
We're not expecting Teva Pharmaceutical Industries to pay a dividend over the next 12 months. However, you can browse other dividend-paying shares in our guide.
Teva Pharmaceutical Industries's shares were split on a 2:1 basis on 1 July 2004. So if you had owned 1 share the day before before the split, the next day you'd have owned 2 shares. This wouldn't directly have changed the overall worth of your Teva Pharmaceutical Industries shares – just the quantity. However, indirectly, the new 50% lower share price could have impacted the market appetite for Teva Pharmaceutical Industries shares which in turn could have impacted Teva Pharmaceutical Industries's share price.
Over the last 12 months, Teva Pharmaceutical Industries's shares have ranged in value from as little as $6.25 up to $13.56. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Teva Pharmaceutical Industries's is 1.4958. This would suggest that Teva Pharmaceutical Industries's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Subscribe to trending stock alerts for a chance to win
Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, and internationally. The company offers sterile products, hormones, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments, and creams. It also develops, manufactures, and sells active pharmaceutical ingredients. In addition, the company provides specialty medicines for use in central nervous system and respiratory indications. Further, its products in the central nervous system and pain area comprise Copaxone for the treatment of relapsing forms of MS; AJOVY for the preventive treatment of migraine; and AUSTEDO for the treatment of tardive dyskinesia and chorea associated with Huntington disease. Additionally, the company's products in the respiratory market include ProAir, ProAir Respiclick, QVAR, Duoresp Spiromax, Braltus, Cinqair/Cinqaero, and AirDuo RespiClick/ArmonAir RespiClick/AirDuo Digihaler for the treatment of asthma and chronic obstructive pulmonary disease, as well as Bendeka, Treanda, Granix, Trisenox, Lonquex, and Tevagrastim/Ratiograstim products in the oncology market. It has collaboration arrangements with Otsuka Pharmaceutical Co. Ltd. and Regeneron Pharmaceuticals, Inc. Teva Pharmaceutical Industries Limited was founded in 1901 and is headquartered in Petach Tikva, Israel.
Learn more about Transportation and Logistics Systems’ recent performance and where you can invest in Transportation and Logistics Systems shares. We also run through some helpful rules of thumb for any investor.
Learn more about Charlie’s Holdings’ recent performance and where you can invest in Charlie’s Holdings shares. We also run through some helpful rules of thumb for any investor.
Learn more about Lemonade’s recent performance and where you can invest in Lemonade shares. We also run through some helpful rules of thumb for any investor.
Learn more about Unity Software’s recent performance and where you can invest in Unity Software shares. We also run through some helpful rules of thumb for any investor
Learn more about FuelCell Energy’s recent performance and where you can invest in FuelCell Energy shares. We also run through some helpful rules of thumb for any investor.
Learn more about CloudCommerce’s recent performance and where you can invest in CloudCommerce shares. We also run through some helpful rules of thumb for any investor
Ever wondered how to buy shares in Zomedica Pharmaceuticals? We explain how and compare a range of providers that can give you access to many brands, including Zomedica Pharmaceuticals.
Ever wondered how to buy shares in YRC Worldwide? We explain how and compare a range of providers that can give you access to many brands, including YRC Worldwide.
Ever wondered how to buy shares in Xeros Technology Group? We explain how and compare a range of providers that can give you access to many brands, including Xeros Technology Group.
Ever wondered how to buy shares in Xpediator? We explain how and compare a range of providers that can give you access to many brands, including Xpediator.